GLOBAL ORPHAN DRUG PIPELINE ANALYSIS

In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry. With close to 65-70 Million people in the US & Europe having some kind of rare disease complaints, the increasing activities around the development of orphan drugs only imply that the appropriate treatments for unmet needs are increasing, thus increasing the profit margins in the future. As the Asian pharmaceutical markets are still in growth stage, the opportunities for orphan drugs in Asia are also immense and getting increasingly popular. It is expected that by 2020, the Asian orphan drugs market would witness steady growth.

“Global Orphan Drug Pipeline Analysis” gives comprehensive insight on the various orphan designated drugs being developed for the treatment of rare disease. Research report covers all the orphan designated drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Orphan Drug market based upon development process.

Read » Global Orphan Drug Pipeline Analysis

Published 28 weeks 5 days ago
Category: Health | Tags:

Login or register to post comments

Stories similar to Global Orphan Drug Pipeline Analysis:

Additional information on Global Orphan Drug Pipeline Analysis :
- Jun 25, 2014 ... "The global pharmaceutical industry has been experiencing a slow .... Global Orphan Drug Pipeline Insight by Phase, Orphan Designated ...
- Mar 28, 2014 ... The global orphan drugs market presents many opportunities for new ... with true disease-modifying properties,” according to a new analysis.
- Oct 14, 2013 ... Reports titled "US Orphan Drug Pipeline Analysis" and "Europe Orphan Drug Pipeline Analysis" include insight on all the orphan drugs being ...
- Mar 22, 2014 ... ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug ...
- Dec 16, 2013 ... Chief Executive Officer, Center for Applied Value Analysis, New York, NY .... US and Global Payer Policies for Orphan Drugs Health insurance ...
- Global Orphan Drug Pipeline Insight by Phase, Orphan Designated Disease .... As the finished drug cannot be analyzed to intricate details, the orphan drug ...
- Keywords: Exclusivity, incentives, orphan drug, pipeline drugs, rare diseases .... The global orphan drugs market reached $84.9 billion in 2009 growing from ...
- Mar 25, 2014 ... New analysis from Frost & Sullivan's Product and Pipeline Assessment of the Global Orphan Drugs Market identifies rare cancers as the orphan ...

Related links about Global Orphan Drug Pipeline Analysis :
1. Orphan Drugs Market 2018 Outlook and Pipeline Analysis ...
2. Drug Developers Drawn to Orphan Drugs Market: Financial ...
3. U.S., Europe poised to dominate global orphan drug market in terms ...
4. Orphan drugs: fiscal incentives "generating rich R&D pipelines"
5. Global Orphan Drug Market to Reach USD 120 Billion by 2018 ...

Global Orphan Drug Pipeline Analysis 1 year 8 weeks ago: In recent years, the pharmaceutical industry has been experiencing a paradigm shift. While a large pool of patients was considered as a major source of revenue for pharma companies in the past, the focus is now gradually shifting to small sections of patients suffering from rare disease. In US & Europe, this pool of patients is gradually growing and orphan drugs are becoming an extremely attractive business proposition for the pharmaceuticals industry.
Orphan Drugs for Cancer Pipeline Analysis 1 year 13 weeks ago: “Orphan Drugs for Cancer Pipeline Analysis” gives comprehensive insight on the various orphan designated drugs being developed for the treatment of multiple cancers. Research report covers all the ongoing vaccines being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the market for orphan designated cancer drugs based upon development process.
Global Orphan Drug Pipeline & Regulatory Insight 2015 6 weeks 4 days ago: Rare diseases are also known as Orphan diseases. These diseases are generally categorized as chronic, degenerative, life threatening in nature and normally include certain cancers, metabolic conditions, diseases of the nervous system and musculoskeletal disorders. As per the official definition, rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in the EU. These two regions form a dominant portion of the global market for orphan drugs.
Global Orphan Cancer Drug Market & Clinical Pipeline Insight 2 weeks 3 days ago: The drug development strategies of the pharmaceutical companies is undergoing a paradigm shift from manufacturing traditional essential medicines to orphan drugs due to significant competition from generics and the associated economic situation. The returns on investment from orphan drugs are expected to help the pharma companies to overcome the impact of revenue loss due to expiry of patents of blockbuster drugs.
Global Orphan Drug Market Outlook 1 year 3 days ago: The global pharmaceutical industry has been experiencing a slow growth in recent years owing to many factors such as expiration of patents, competition from generic drugs segment, exhausting pipelines, and an increasingly stringent regulatory framework. It is most likely that many blockbuster drugs would lose their exclusivity in the next 5 year horizon.